BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Hereditary angioedema clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for hereditary angioedema: 25 (12 sponsors; 1 newly posted in the last 180 days, 1 stopped in the last 180 days; 1 new-entrant sponsors). Momentum score 26, rank 11 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 0, Phase 2 5, Phase 3 13, Phase 4 1, N/A 6.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Pharvaris Netherlands B.V. PHVS | 3 | P3 3 | 0 | 0 |
| ADARx Pharmaceuticals, Inc. ADRX | 3 | P3 2, P2 1 | 0 | 0 |
| Astria Therapeutics, Inc. | 3 | P3 2, P2 1 | 0 | 1 |
| BioCryst Pharmaceuticals BCRX | 2 | P3 2 | 0 | 0 |
| Ionis Pharmaceuticals, Inc. IONS | 2 | P3 2 | 0 | 1 |
| Intellia Therapeutics NTLA | 3 | P2 1, NA 1, P3 1 | 0 | 0 |
| Octapharma | 1 | P3 1 | 0 | 1 |
| Takeda TAK | 4 | NA 4 | 0 | 1 |
| BioMarin Pharmaceutical BMRN | 1 | P2 1 | 0 | 0 |
| CSL Behring | 1 | NA 1 | 0 | 0 |
| KalVista Pharmaceuticals, Ltd. new entrant | 1 | P4 1 | 1 | 0 |
| Shanghai Argo Biopharmaceutical Co., Ltd. | 1 | P2 1 | 0 | 0 |
New-entrant sponsors: KalVista Pharmaceuticals, Ltd..
Recently stopped trials
- NCT05047185 Pharvaris Netherlands B.V. - terminated: Sponsor decision. All remaining participants (21 total) were rolled over from Part 2 to study PHA022121-C307 (NCT06679881). Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | Ionis Pharmaceuticals, Inc. IONS | NCT05392114 A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | Hereditary Angioedema | active not recruiting | 154 |
| 2026-12 est. | P3 | Astria Therapeutics, Inc. | NCT06842823 A Study of Navenibart in Participants With Hereditary Angioedema | Hereditary Angioedema (HAE) | active not recruiting | 157 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-07-21 | P3 | Pharvaris Netherlands B.V. PHVS | NCT06669754 Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE | Hereditary Angioedema (HAE) | completed | 85 |
| 2026-06-30 est. | P2 | Shanghai Argo Biopharmaceutical Co., Ltd. | NCT06846398 A Phase 2 in Adult Subjects With Hereditary Angioedema | Hereditary Angioedema (HAE) | active not recruiting | 25 |
| 2026-05-27 | P3 | KalVista Pharmaceuticals, Ltd. | NCT05511922 PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial | Hereditary Angioedema | completed | 11 |
| 2026-05-27 | P3 | KalVista Pharmaceuticals, Ltd. | NCT05505916 An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Pa | Hereditary Angioedema | completed | 145 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "hereditary angioedema"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.